Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Halofuginone hydrobromide; HT-100; Stenorol™; Tempostatin™

Latest Information Update: 21 Jul 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Collgard Biopharmaceuticals
  • Developer Akashi Therapeutics; Collgard Biopharmaceuticals
  • Class Antifibrotics; Piperidines; Quinazolinones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Collagen type I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy; Scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy
  • Discontinued Bladder cancer; Cancer; Coronary artery restenosis; Hepatic fibrosis; Kidney disorders; Renal fibrosis; Scleroderma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 21 Apr 2017 Akashi Therapeutics terminates the HALO-DMD-03 phase II trial for Duchenne muscular dystrophy in USA (NCT02525302)
  • 21 Apr 2017 Akashi Therapeutics terminates the phase II HALO extension trial for Duchenne muscular dystrophy in USA as the dosing was stopped (PO) (NCT01978366)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top